Expression of the Polycomb-Group Protein BMI1 and correlation with p16 in astrocytomas. An immunohistochemical study on 80 cases

Pathology Research and Practice

Volumn 204, Issue 9, 2008, Pages 625-631

  Tirabosco, Roberto ^a   De Maglio, Giovanna ^b   Skrap, Miran ^b   Falconieri, Giovanni ^b   Pizzolitto, Stefano ^b  

^a ROYAL NATIONAL ORTHOPAEDIC HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITAL OF UDINE   (Italy)

Author keywords

Brain tumors; Carcinogenesis; Gliomas; Polycomb Group Protein

Indexed keywords

BMI1 PROTEIN; PROTEIN P16;

ADULT; AGED; ARTICLE; ASTROCYTOMA; CANCER GRADING; CARCINOGENESIS; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOLOGY; FEMALE; GENE EXPRESSION PROFILING; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING;

ASTROCYTOMA; BRAIN NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; NUCLEAR PROTEINS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; REPRESSOR PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 49749101982     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2008.02.007     Document Type: Article

References (36)

1. Arifin M.T., Hama S., Kajiwara Y., Sugiyama K., Saito T., Matsuura S., Yamasaki F., Arita K., and Kurisu K. Cytoplasmic, but not nuclear, p16 expression may signal poor prognosis in high-grade astrocytomas. J. Neurooncol. 77 (2006) 273-277
2. Avninder S., Sharma M.C., Deb P., Mehta V.S., Karak A.K., Mahapatra A.K., and Sarkar C. Gemistocytic astrocytomas: histomorphology, proliferative potential and genetic alterations - a study of 32 cases. J. Neurooncol. 78 (2006) 123-127
3. Bea S., Tort F., Pinyol M., Puig X., Hernandez L., Hernandez S., Fernandez P.L., van Lohuizen M., Colomer D., and Campo E. BMI-1 gene amplification and overexpression in hematological malignancies occur mainly in mantle cell lymphomas. Cancer Res. 61 (2001) 2409-2412
4. Berezovska O.P., Glinskii A.B., Yang Z., Li X.M., Hoffman R.M., and Glinsky G.V. Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer. Cell Cycle 5 (2006) 1886-1901
5. Breuer R.H., Snijders P.J., Sutedja G.T., Sewalt R.G., Otte A.P., Postmus P.E., Meijer C.J., Raaphorst F.M., and Smit E.F. Expression of the p16(INK4a) gene product, methylation of the p16(INK4a) promoter region and expression of the polycomb-group gene BMI-1 in squamous cell lung carcinoma and premalignant endobronchial lesions. Lung Cancer 48 (2005) 299-306
6. Dimri G.P., Martinez J.L., Jacobs J.J., Keblusek P., Itahana K., Van Lohuizen M., Campisi J., Wazer D.E., and Band V. The Bmi-1 oncogene induces telomerase activity and immortalizes human mammary epithelial cells. Cancer Res. 62 (2002) 4736-4745
7. Glinsky G.V., Berezovska O., and Glinskii A.B. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J. Clin. Invest. 115 (2005) 1503-1521
8. Homma T., Fukushima T., Vaccarella S., Yonekawa Y., Di Patre P.L., Franceschi S., and Ohgaki H. Correlation among pathology, genotype, and patient outcomes in glioblastoma. J. Neuropathol. Exp. Neurol. 65 (2006) 846-854
9. Kim J.H., Yoon S.Y., Kim C.N., Joo J.H., Moon S.K., Choe I.S., Choe Y.K., and Kim J.W. The Bmi-1 oncoprotein is overexpressed in human colorectal cancer and correlates with the reduced p16INK4a/p14ARF proteins. Cancer Lett. 203 (2004) 217-224
10. P. Kleihues, W.K. Cavenee, Pathology and Genetics of Tumours of the Nervous System, International Agency for Research on Cancer, IARC Press, Lyon.
11. Kosel S., Scheithauer B.W., and Graeber M.B. Genotype-phenotype correlation in gemistocytic astrocytomas. Neurosurgery 48 (2001) 187-193 (discussion 193-184)
12. Kros J.M., Waarsenburg N., Hayes D.P., Hop W.C., and van Dekken H. Cytogenetic analysis of gemistocytic cells in gliomas. J. Neuropathol. Exp. Neurol. 59 (2000) 679-686
13. Leung C., Lingbeek M., Shakhova O., Liu J., Tanger E., Saremaslani P., Van Lohuizen M., and Marino S. Bmi1 is essential for cerebellar development and is overexpressed in human medulloblastomas. Nature 428 (2004) 337-341
14. Liu L., Andrews L.G., and Tollefsbol T.O. Loss of the human polycomb group protein BMI1 promotes cancer-specific cell death. Oncogene 25 (2006) 4370-4375
15. Martins D.C., Malheiros S.M., Santiago L.H., and Stavale J.N. Gemistocytes in astrocytomas: are they a significant prognostic factor?. J. Neurooncol. 80 (2006) 49-55
16. Molofsky A.V., Pardal R., Iwashita T., Park I.K., Clarke M.F., and Morrison S.J. Bmi-1 dependence distinguishes neural stem cell self-renewal from progenitor proliferation. Nature 425 (2003) 962-967
17. Nakahara Y., Shiraishi T., Okamoto H., Mineta T., Oishi T., Sasaki K., and Tabuchi K. Detrended fluctuation analysis of genome-wide copy number profiles of glioblastomas using array-based comparative genomic hybridization. Neuro-oncology 6 (2004) 281-289
18. Nowak K., Kerl K., Fehr D., Kramps C., Gessner C., Killmer K., Samans B., Berwanger B., Christiansen H., and Lutz W. BMI1 is a target gene of E2F-1 and is strongly expressed in primary neuroblastomas. Nucleic Acids Res. 34 (2006) 1745-1754
19. Ranuncolo S.M., Varela M., Morandi A., Lastiri J., Christiansen S., Bal de Kier Joffè E., Pallotta M.G., and Puricelli L. Prognostic value of Mdm2, p53 and p16 in patients with astrocytomas. J. Neurooncol. 68 (2004) 113-121
20. Reis R.M., Hara A., Kleihues P., and Ohgaki H. Genetic evidence of the neoplastic nature of gemistocytes in astrocytomas. Acta Neuropathol. (Berl.) 102 (2001) 422-425
21. Sanchez-Beato M., Sanchez E., Gonzalez-Carrero J., Morente M., Diez A., Sanchez-Verde L., Martin M.C., Cigudosa J.C., Vidal M., and Piris M.A. Variability in the expression of polycomb proteins in different normal and tumoral tissues. A pilot study using tissue microarrays. Mod. Pathol. 19 (2006) 684-694
22. Shakhova O., Leung C., and Marino S. Bmi1 in development and tumorigenesis of the central nervous system. J. Mol. Med. 83 (2005) 596-600
23. Song L.B., Zeng M.S., Liao W.T., Zhang L., Mo H.Y., Liu W.L., Shao J.Y., Wu Q.L., Li M.Z., Xia Y.F., Fu L.W., Huang W.L., Dimri G.P., Band V., and Zeng Y.X. Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells. Cancer Res. 66 (2006) 6225-6232
24. Tateishi K., Ohta M., Kanai F., Guleng B., Tanaka Y., Asaoka Y., Tada M., Seto M., Jazag A., Lianjie L., Okamoto M., Isayama H., Tada M., Yoshida H., Kawabe T., and Omata M. Dysregulated expression of stem cell factor Bmi1 in precancerous lesions of the gastrointestinal tract. Clin. Cancer Res. 12 (2006) 6960-6966
25. Tihan T., Vohra P., Berger M.S., and Keles G.E. Definition and diagnostic implications of gemistocytic astrocytomas: a pathological perspective. J. Neurooncol. 76 (2006) 175-183
26. Valk-Lingbeek M.E., Bruggeman S.W., and van Lohuizen M. Stem cells and cancer; the polycomb connection. Cell 118 (2004) 409-418
27. van der Lugt N.M., Domen J., Linders K., van Roon M., Robanus-Maandag E., te Riele H., van der Valk M., Deschamps J., Sofroniew M., van Lohuizen M., et al. Posterior transformation, neurological abnormalities, and severe hematopoietic defects in mice with a targeted deletion of the bmi-1 proto-oncogene. Genes Dev. 8 (1994) 757-769
28. van Kemenade F.J., Raaphorst F.M., Blokzijl T., Fieret E., Hamer K.M., Satijn D.P., Otte A.P., and Meijer C.J. Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma. Blood 97 (2001) 3896-3901
29. van Leenders G.J., Dukers D., Hessels D., van den Kieboom S.W., Hulsbergen C.A., Witjes J.A., Otte A.P., Meijer C.J., and Raaphorst F.M. Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features. Eur. Urol. (2006)
30. Voncken J.W., Schweizer D., Aagaard L., Sattler L., Jantsch M.F., and van Lohuizen M. Chromatin-association of the Polycomb group protein BMI1 is cell cycle-regulated and correlates with its phosphorylation status. J. Cell Sci. 112 Part 24 (1999) 4627-4639
31. Voncken J.W., Niessen H., Neufeld B., Rennefahrt U., Dahlmans V., Kubben N., Holzer B., Ludwig S., and Rapp U.R. MAPKAP kinase 3pK phosphorylates and regulates chromatin association of the polycomb group protein Bmi1. J. Biol. Chem. 280 (2005) 5178-5187
32. Vonlanthen S., Heighway J., Altermatt H.J., Gugger M., Kappeler A., Borner M.M., van Lohuizen M., and Betticher D.C. The bmi-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4A-ARF locus expression. Br. J. Cancer 84 (2001) 1372-1376
33. Watanabe K., Tachibana O., Yonekawa Y., Kleihues P., and Ohgaki H. Role of gemistocytes in astrocytoma progression. Lab. Invest. 76 (1997) 277-284
34. Watanabe K., Peraud A., Gratas C., Wakai S., Kleihues P., and Ohgaki H. p53 and PTEN gene mutations in gemistocytic astrocytomas. Acta Neuropathol. (Berl.) 95 (1998) 559-564
35. Yang H.J., Kim J.E., Paek S.H., Chi J.G., Jung H.W., and Kim D.G. The significance of gemistocytes in astrocytoma. Acta Neurochir. (Wien) 145 (2003) 1097-1103 (discussion 1103)
36. Zencak D., Lingbeek M., Kostic C., Tekaya M., Tanger E., Hornfeld D., Jaquet M., Munier F.L., Schorderet D.F., van Lohuizen M., and Arsenijevic Y. Bmi1 loss produces an increase in astroglial cells and a decrease in neural stem cell population and proliferation. J. Neurosci. 25 (2005) 5774-5783